Last reviewed · How we verify
scopolamine transdermal
Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting.
Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting. Used for Prevention of motion sickness, Prevention of postoperative nausea and vomiting.
At a glance
| Generic name | scopolamine transdermal |
|---|---|
| Also known as | Transderm Scop |
| Sponsor | Stony Brook University |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors (M1, M3, M5) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Antiemetics |
| Phase | FDA-approved |
Mechanism of action
Scopolamine is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors, particularly in the chemoreceptor trigger zone and vestibular nuclei of the brain. By blocking these receptors, it suppresses signals that trigger nausea and vomiting. The transdermal formulation provides sustained drug delivery over several days, making it effective for motion sickness and postoperative nausea prevention.
Approved indications
- Prevention of motion sickness
- Prevention of postoperative nausea and vomiting
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Mydriasis (dilated pupils)
Key clinical trials
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
- Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study (PHASE4)
- Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery? (PHASE3)
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
- A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness (PHASE3)
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness (PHASE3)
- Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- scopolamine transdermal CI brief — competitive landscape report
- scopolamine transdermal updates RSS · CI watch RSS
- Stony Brook University portfolio CI